Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Herbert, MK; Holzer, P.
Innovative treatment of acute migraine pain with CGRP receptor antagonists
ANASTHESIOL INTENS N. 2004; 39: 657-661.
Doi: 10.1055/s-2004-826037
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Herbert Michael K.
- Co-authors Med Uni Graz
- Holzer Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Neurogenic inflammation caused by the release of vasoactive neuropeptides such as calcitonin gene-related peptide (CGRP) from nociceptive perivascular nerve fibres has been implicated in the development of acute migraine pain. It has recently been demonstrated that the CGRP receptor antagonist BIBN 4096 BS significantly reduces acute pain in migraine. This therapeutic efficacy provides further evidence for a critical role of CGRP in the pathophysiology of migraine. Given the apparent absence of vasoconstrictor activity both in meningeal and extracranial vessels, BIBN 4096 BS may provide an alternative for the treatment of migraine in those patients where triptans and ergotamine derivatives are contraindicated due to their side effects.
- Find related publications in this database (using NLM MeSH Indexing)
- Calcitonin Gene-Related Peptide - analogs and derivatives
- English Abstract - analogs and derivatives
- Humans - analogs and derivatives
- Migraine Disorders - drug therapy
- Piperazines - therapeutic use
- Quinazolines - therapeutic use
- Receptors, Calcitonin Gene-Related Peptide - antagonists and inhibitors
- Vasodilator Agents - therapeutic use
- Find related publications in this database (Keywords)
- CGRP receptor antagonist
- BIBN4096BS
- migraine
- neurogenic inflammation
- triptans